JMP Securities Reiterates Market Outperform on Protagonist Therapeutics, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating for Protagonist Therapeutics (NASDAQ:PTGX) and maintained a price target of $45.
June 17, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating for Protagonist Therapeutics and maintained a price target of $45, indicating strong confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $45 by JMP Securities suggests strong confidence in Protagonist Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100